Intuitive Surgical (ISRG) News Today

Intuitive Surgical, Inc. (NASDAQ: ISRG) is seeing mixed investor sentiment as shares approach the company’s third-quarter earnings report. Positive analyst views and enthusiasm about robotic-surgery growth are being balanced by valuation concerns and the need for strong results to support the recent rally.

• Positive Sentiment: ISRG shares have gained nearly 12% over the past month, supported by increasing adoption of the da Vinci 5 surgical system and continued growth in the Ion robotic platform. ISRG Gains Nearly 12% in a Month
• Positive Sentiment: Zacks upgraded Intuitive Surgical to Rank #2, or Buy, citing improving earnings prospects. UBS also reiterated a Buy rating and maintained a $500 price target, pointing to the company’s long-term robotic-surgery growth runway. ISRG Upgraded to Buy UBS Reiterates Buy Rating
• Positive Sentiment: Intuitive Surgical is pursuing growth beyond surgery after submitting a next-generation robotic endoscope to the FDA for gastrointestinal procedures. Approval could create a sizable new market, although timing and regulatory clearance remain uncertain. ISRG Expanding Beyond Surgery
• Positive Sentiment: Erste Group modestly raised its Intuitive Surgical earnings estimates to $8.94 per share for fiscal 2026 and $10.09 for fiscal 2027, above its prior forecasts and the broader current-year consensus of $8.87. Erste Group Earnings Estimate Changes

• Neutral Sentiment: Investors are focused on the upcoming third-quarter earnings report. The results, procedure growth, da Vinci 5 demand and management’s outlook will likely determine whether the recent momentum continues. ISRG Expected to Post Quarterly Earnings

• Negative Sentiment: Despite the favorable outlook, commentary warns that ISRG may be roughly 31% overvalued after its earnings-outlook upgrade. Its elevated valuation leaves the stock vulnerable to a pullback if quarterly results or forward guidance fall short of high expectations. ISRG Could Be Overvalued